We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
News

Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China

Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
News

Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Life Technologies DaAn Diagnostics with its headquarters in Guangzhou, will develop and commercialize a portfolio of molecular diagnostic assays using Life Technologies' 3500Dx Capillary Electrophoresis instrument and the Big Dye® Cycle Sequencing technologies, focused on IVD assays for oncology, infectious and genetic diseases. The joint venture allows both companies to expand the use of Capillary Electrophoresis technology into the Chinese clinical diagnostics market.

"This joint venture strengthens the foundation of our clinical diagnostics business and represents a big leap forward for our business in China," said Gregory Lucier, Chairman and CEO of Life Technologies.  "As a leading biotechnology company, we are at the forefront of a rapidly evolving healthcare landscape. This joint venture and its products will play a key role in disease prevention and therapy selection and is complementary to the Chinese government's 12th five-year plan to promote national economic and social development."

"The joint venture will help us offer leading medical diagnostic technologies with cost-effective solutions to Chinese healthcare professionals," said Dr. Siddhartha Kadia, President of Life Technologies, Greater China. "This approach leverages our expertise in platform development and DaAn's expertise in regulated markets with kit development and commercialization."

"Twenty years ago, the cooperation between DaAn and Applied Biosystems brought PCR technology into China's molecular diagnostic field, positioning China with the most potential to become the world's largest PCR market for clinical diagnostics. Today, the cooperation with Life Technologies introduces DaAn's products to the global marketplace, while bringing Life's superior technologies into China's IVD market. Together, we are working toward becoming a premium IVD product supplier that has global impact," said Zhou Xinyu, CEO of DaAn Gene.

Life Technologies' 3500Dx instrument is a capillary-based Sanger Sequencer intended for use in the analysis of human DNA for the detection of genetic changes that may lead to disease presence or improved response to various therapies.  Life Technologies' Sanger Sequencers supplied the technology that powered the Human Genome Project.  Sanger instruments remain the sequencing gold-standard for accuracy, reliability and ease of use. The 3500Dx Genetic Analyzer was approved by China State Food and Drug Administration (SFDA) for IVD diagnostic use in China in October 2011.

Advertisement